 
        The Use of Various Antithrombotic Agents for Venous Thromboembolism Prophylaxis After TKA
 
                                                    The Use of Various Antithrombotic Agents for Venous Thromboembolism Prophylaxis After TKA
Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized study.
BMC Musculoskelet Disord . 2023 Jan 4;24(1):5.Synopsis
One hundred and eighty patients undergoing primary unilateral total knee arthroplasty were randomized to receive either rivaroxaban (n=60), dalteparin sodium (n=60), or aspirin (n=60) once a day for 30 days. The primary outcomes of interest were drainage volume and thrombotic complication rates. Secondary outcomes of interest included platelet count, blood volume, transfusion rate, intraoperative ...
                To view the full content, login to your account,
or start your 30-day FREE Trial today.
            
            FREE TRIAL
            LOGIN
            Forgot Password?
    Explore some of our unlocked ACE Reports below!
 
                Learn about our AI Driven 
 High Impact Search Feature
     
    Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue 
                     
                 
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         
                                                         LOGIN
                                    LOGIN
                                 
            
Join the Conversation
Please Login or Join to leave comments.